Clinical Trial Update: An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression [Phase 3]

View source ↗

Summary

An eight-week Phase 3 trial assessing the efficacy and safety of Saredutant in Depressive Disorder patients, sponsored by Sanofi; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder

Drugs mentioned

• Saredutant (saredutant)

Snippet

Sponsor: Sanofi | Conditions: Depressive Disorder | Phase 3 | Status: COMPLETED